Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.80 |
| ▸ | DPP4 | P27487 | 1/20 | 0.80 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | G6PD | P11413 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384234 | 1.00 | AKR1B1 (0.80) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL30383483 | 1.00 | AKR1B1 (0.80) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL25221633 | 1.00 | AKR1B1 (0.80) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL30092342 | 1.00 | AKR1B1 (0.80) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL25200498 | 0.93 | AKR1B1 (0.79) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL25203608 | 0.93 | AKR1B1 (0.79) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL2958166 | 0.93 | AKR1B1 (0.79) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL30168488 | 0.93 | AKR1B1 (0.79) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL30383207 | 0.93 | AKR1B1 (0.79) | AKR1B1DPP4GAATDP1NPC1 | |
| SCHEMBL25195327 | 0.93 | AKR1B1 (0.92) | AKR1B1DPP4GAATDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | AKR1B1 2220/4885DPP4 4226/4885GAA 1372/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | AKR1B1 2215/4885DPP4 3670/4885GAA 1183/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | AKR1B1 2215/4885DPP4 3670/4885GAA 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.